Cargando…

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study

PURPOSE: The exposure–response relationships for efficacy and safety of ipatasertib, a selective AKT kinase inhibitor, were characterized using data collected from 1101 patients with metastatic castration-resistant prostate cancer in the IPATential150 study (NCT03072238). METHODS: External validatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotani, Naoki, Wilkins, Justin J., Wade, Janet R., Dang, Steve, Sutaria, Dhruvitkumar S., Yoshida, Kenta, Sundrani, Sameer, Ding, Hao, Garcia, Josep, Hinton, Heather, Sane, Rucha, Chanu, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637074/ https://www.ncbi.nlm.nih.gov/pubmed/36305957 http://dx.doi.org/10.1007/s00280-022-04488-2

Ejemplares similares

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
por: Jing, Jing, et al.
Publicado: (2022)

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics
por: Yoshida, Kenta, et al.
Publicado: (2018)

Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
por: O'donnell, Jillian, et al.
Publicado: (2023)

Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
por: Laterza, Maria Maddalena, et al.
Publicado: (2021)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer
por: Zhu, Rui, et al.
Publicado: (2019)

The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer
por: THAKKAR, ARVIND, et al.
Publicado: (2013)

Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen
por: SUTARIA, DHRUVITKUMAR, et al.
Publicado: (2012)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
por: Shi, Zhen, et al.
Publicado: (2022)

Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
por: Sun, Li, et al.
Publicado: (2018)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
por: Turner, Nicholas, et al.
Publicado: (2021)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Canada 150
por: D’Eon, Marcel
Publicado: (2017)

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
por: Bulitta, Jürgen B., et al.
Publicado: (2019)

Predicting patient decompensation from continuous physiologic monitoring in the emergency department
por: Sundrani, Sameer, et al.
Publicado: (2023)

150 masterpieces of drawing
Publicado: (1963)

150 grandes científicos
por: Bridge, Norman J.
Publicado: (1992)

150 Carcinogenesis of HPV
por: Buonaguro, FM, et al.
Publicado: (2014)

£150,000 Required
Publicado: (1919)

150 actividades : juegos de naturaleza
Publicado: (2001)

Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2017)

MicroRNA-150 (miR-150) and Diabetic Retinopathy: Is miR-150 Only a Biomarker or Does It Contribute to Disease Progression?
por: Ko, Gladys Y.-P., et al.
Publicado: (2022)

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
por: Guan, Jikui, et al.
Publicado: (2015)

150 science experiments : step-by-step /
por: Viorst, Judith
Publicado: (1967)

miR-150-PTPMT1-cardiolipin signaling in pulmonary arterial hypertension
por: Russomanno, Giusy, et al.
Publicado: (2020)

150 problemas de ECG/
por: Hampton, John R.
Publicado: (2009)

150th LHCC Meeting
Publicado: (2022)

150th SPSC Meeting
Publicado: (2023)

Hospitals under 150 Beds
Publicado: (1916)

Hospitals with 150 Beds and Upwards
Publicado: (1916)

Hospitals under 150 Beds
Publicado: (1918)

Hospitals with 150 Beds and Upwards
Publicado: (1918)

P150 Abstract Withdrawn
Publicado: (2021)

Castration
por: Pugh, T. J.
Publicado: (1897)

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding
por: Shah, Nirav R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gkn4ubqk3nst7ifilc6hu4t851